Results 61 to 70 of about 9,672 (236)

Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
Targeting host signaling pathways offers a complementary strategy to direct‐acting antivirals. Small‐molecule modulators of atypical p38 block Hepatitis C virus replication and also inhibit Human Cytomegalovirus. By disrupting virus‐induced p38 activation, these compounds suppress viral RNA replication and protein expression, highlighting atypical p38 ...
Fredejah T. Royer, Jeremy C. Burton, Johnathan Burns, Megan G. Lloyd, Reuben Onwe, Jennifer F. Moffat, Neil J. Grimsey   +6 more
wiley   +1 more source

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.

PLoS ONE, 2023
BackgroundInsurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig   +3 more
doaj   +1 more source

All-oral direct-acting Antiviral Therapy Against Hepatitis C Virus (HCV) in Human Immunodeficiency Virus/HCV– Coinfected Subjects in Real-World Practice: Madrid Coinfection Registry Findings [PDF]

, 2018
We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)–coinfected patients treated with interferon-free direct-acting antiviral agent–based therapy in hospitals from the region of Madrid between
Abergel, Afdhal, Afdhal, Afdhal, Ahlen, Arias, Backus, Berenguer, Bhattacharya, Boesecke, European Association for the Study of the Liver, European Association for the Study of the Liver, Feld, Feld, Franchis, Gane, Gao, Hawkins, Hezode, Ingiliz, Ioannou, Kowdley, Kowdley, Kowdley, Leroy, Liang, Montes, Naggie, Nelson, Pawlotsky, Piroth, Poordad, Rockstroh, Saeed, Singh, Smith, Sogni, Sulkowski, Tapper, Terrault, Zeuzem, Zeuzem   +41 more
core   +3 more sources

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C

Anales de Pediatría, 2019
Resumen: Introducción: El objetivo del estudio fue evaluar la seguridad y la eficacia de la combinación de ledipasvir/sofosbuvir en la infección crónica por el genotipo 1 y 4 del virus de la hepatitis C (VHC) en pacientes pediátricos.
Jesús Quintero, Javier Juampérez, Ecaterina Julio, Vanessa Cabello, Maria Mercadal-Hally, Pere Soler-Palacín, Óscar Segarra, Carlos Rodrigo   +7 more
doaj   +1 more source

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Informatics in Medicine Unlocked, 2021
Background: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results ...
Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh   +3 more
doaj   +1 more source

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. [PDF]

, 2018
AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe ...
Aby, Elizabeth S, Benhammou, Jihane N, Dong, Tien S, Han, Steven-Huy, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +6 more
core  

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major [PDF]

, 2017
Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3].
Biliotti, Elisa, Esvan, Rozenn, Franchi, Cristiana, Palazzo, Donatella, Serani, Marco, Silvestri, Alessandro M., Sorrentino, Francesco, Spaziante, Martina, Taliani, Gloria, Volpicelli, Lorenzo   +9 more
core   +1 more source

Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial [PDF]

, 2022
Donna M. Evon, Meichen Dong, Bryce B. Reeve, Joy Peter, Larry Michael, Anna S. Lok, David R. Nelson, Paul W. Stewart   +7 more
openalex   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]

, 2016
[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S., Ampuero, J., Badia, E., Baliellas, C., Buti, M., Carrión, J.A., Castro-Iglesias, Ángeles, Devesa, M.J., Esteban, R., Fernández, I., Fernández-Carrillo, C., Fernández-Rodríguez, C.M., Gea, F., Granados, R., Gómez, A., Lens, S., Llerena, S., Montero, J.L., Olveira, A., Pascasio, J.M., Planas, J.M.M., Polo, B., Real, Y., Rincón, D., Riveiro-Barciela, M., Rubín, A., Salmerón, J., Turnes, J.   +27 more
core   +2 more sources